levomilnacipran
The US Food and Drug Administration has approved Forest Laboratories and Pierre Fabre’s Fetzima for major depressive disorder.
Fetzima (levomilnacipran extended-release), a once-daily serotonin and norepinephrine reuptake inhibitor, has been given the green light based on Phase III studies of adults with MDD and statistically significant and clinically meaningful improvement in depressive symptoms across three doses (40, 80, and 120 mg).
read all at
http://www.pharmatimes.com/Article/13-07-26/US_OK_for_Forest_Pierre_Fabre_antidepressant.aspx
Levomilnacipran (F2695) is an antidepressant currently under development by Forest Laboratories for the treatment of depression in the United States and Canada.[1][2][3] As of 2009 it is in phase III clinical trials.[4] Levomilnacipran is an active enantiomer of milnacipran and therefore has similar effects and pharmacology, acting as a serotonin-norepinephrine reuptake inhibitor.[2][5] On 20 January 2011, Forest and Pierre Fabre Medicament announced that levomilnacipran was no better than placebo in a late-stage clinical trial. Two other late-stage trials will be finished in mid-2011.
References
- “Future Treatments for Depression, Anxiety, Sleep Disorders, Psychosis, and ADHD — Neurotransmitter.net”.
- “Pierre Fabre Medicament and Forest Laboratories to Collaborate on Development and Commercialization of F2695 for Depression – FierceBiotech”.
- “News: Forest Buys CNS Disease-Related Drug for $75M Upfront.”.
- “Search of: F2695 – List Results – ClinicalTrials.gov”.
- Deprez D, Chassard D, Baille P, Mignot A, Ung HL, Puozzo C (1998). “Which bioequivalence study for a racemic drug? Application to milnacipran”. European Journal of Drug Metabolism and Pharmacokinetics 23 (2): 166–71. PMID 9725476.